Why access to an experimental drug takes more than a prescription
A prescription is normally enough to direct a pharmacy to dispense an approved medicine. An investigational drug is different: it has not been cleared for general use, so its safety, effectiveness, or both are still being studied. Giving it to someone outside a clinical trial therefore requires a special path, not just a clinician’s decision.
In the United States, one such path is expanded access, often called compassionate use. A physician must determine that the treatment may help a patient with a serious condition who has no satisfactory alternative, and that using it will not interfere with the drug’s clinical development. The request also needs review through the relevant federal process, which may involve the Food and Drug Administration and an ethics review board.
The manufacturer is a necessary gatekeeper
Regulatory permission does not make a company supply the drug. The manufacturer must agree to provide it and may have limited doses, production capacity, or information about safe use. It also has to consider whether supplying the drug is feasible while trials and development continue. A patient can therefore meet the medical criteria and still be unable to obtain the treatment.
The paperwork helps establish who is responsible for monitoring the patient, reporting side effects, and handling the drug. Liability and other legal arrangements may also need to be addressed between the parties. These steps are not merely administrative: with an unapproved treatment, clinicians have less certainty about risks, dosing, and whether the drug will work.
Permission is not proof of benefit
Expanded access is intended to make a possible option available when ordinary treatments are inadequate, not to certify that the drug is effective. The distinction matters: a patient may face a serious illness and still encounter delay or refusal because the treatment is experimental, the supply is scarce, or the risks cannot be responsibly managed. That is why access depends on several decisions—and why a doctor’s prescription alone cannot unlock the medicine.
